Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 131

Sort by

Sort Order Select

Journal Articles

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 6746.

https://doi.org/10.1182/blood-2024-208444

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2024-204040

Published: 2024

Journal Articles

A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4 + T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Juan Jose Rodriguez Sevilla, Yang Liu, Irene Ganan-Gomez, Vera Adema, Kelly S. Chien, Guillermo Montalban-Bravo, Natthakan Thongon, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna, Sanam Loghavi, Hui Yang, Linghua Wang, Simona Colla

Blood (2024) 144 (Supplement 1): 50.

https://doi.org/10.1182/blood-2024-202641

Published: 2024

Journal Articles

Application of Next-Generation Cytogenetics in a Clinical Laboratory for Diagnostic Work-up of Myelodysplastic Syndromes/Neoplasms (MDS)

Anindita Ghosh, Guilin Tang, Hui Yang, Koji Sasaki, Gokce A. Toruner, Juan Jose Rodriguez-Sevilla, Raja Luthra, Danielle Hammond, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos, Guillermo Montalban-Bravo, Kelly S. Chien, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna

Blood (2024) 144 (Supplement 1): 7519.

https://doi.org/10.1182/blood-2024-211967

Published: 2024

Journal Articles

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Prolymphocytic Leukemia: Two Case Reports

Sihan Lai, Yisong Xiong, Yanrong Shuai, Xupai Zhang, Guangcui He, Hao Yao, Hui Yang, Ling Zhang, Rong Huang, Yi Su, Alex H. Chang, Hai Yi

Blood (2024) 144 (Supplement 1): 7204.

https://doi.org/10.1182/blood-2024-202015

Published: 2024

Journal Articles

CDC2-like Kinases (CLKs) Inhibition As a Novel Targeted Therapeutic Strategy in Myelodysplastic Syndromes (MDS)

Hui Yang, Zhihong Fang, Yue Wei, Juan Jose Rodriguez Sevilla, Marcos Estecio, Guillermo Montalban-Bravo, Kelly S. Chien, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2024-207573

Published: 2024

Journal Articles

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 346.

https://doi.org/10.1182/blood-2024-208106

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2024-205186

Published: 2024

Journal Articles

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Blood (2024) 144 (1): 61–73.

https://doi.org/10.1182/blood.2024023930

Published: 2024

Includes: Supplemental data

Journal Articles

Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones

Blood (2023) 142 (Supplement 1): 514.

https://doi.org/10.1182/blood-2023-184349

Published: 2023

Journal Articles

Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure

Hui Yang, Guillermo Garcia-Manero, Kelly S. Chien, Koji Sasaki, Sherry Pierce, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna

Blood (2023) 142 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2023-187719

Published: 2023

Journal Articles

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Blood (2023) 142 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2023-188961

Published: 2023

Journal Articles

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Juan Jose Rodriguez Sevilla, Vera Adema, Kelly S. Chien, Irene Ganan-Gomez, Guillermo Montalban-Bravo, Samuel Urrutia, Joby Joseph, Hui Yang, Gautam Borthakur, Nicholas J. Short, Ghayas C. Issa, Tapan M. Kadia, Koichi Takahashi, Danielle E. Hammond, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2023-185259

Published: 2023

Journal Articles

Sting-Mediated Interferon Signaling Exerts Potent Antileukemic Effects in High-Risk Myeloid and Monocytic Malignancies

Yue Wei, Ziyi Li, Hui Yang, Hong Zheng, Vicky Appleman, Tiquella Hatten, Yu-Chung Huang, Jeffrey Raizer, Alex Parent, Neil Lineberry, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2023-177985

Published: 2023

Journal Articles

Demographic Characteristics and Treatment Patterns in Veterans with Multiple Myeloma: A Comprehensive Analysis from the Veterans Affairs Database (2000-2020)

Gurbakhash Kaur, Aishwarya Sannareddy, Aaron Perkins, Hui Yang, Somtochukwu Egbuonu, Adeel Khan, Aimaz Afrough, Ankit Kansagra, Larry D. Anderson, Jr., Carlos Alvarez

Blood (2023) 142 (Supplement 1): 7370.

https://doi.org/10.1182/blood-2023-189965

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN)

Blood (2023) 142 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2023-188701

Published: 2023

Journal Articles

No Benefits from Glucocorticoid Maintenance Therapy in Patients with PNH

Hui Yang, Xiaoyu Chen, Yuemin Gong, Yawen Zhang, Jinge Xu, Dan Xu, Jianyong Li, Guangsheng He

Blood (2023) 142 (Supplement 1): 5638.

https://doi.org/10.1182/blood-2023-189210

Published: 2023

Journal Articles

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Samuel Urrutia, Koji Sasaki, Rashmi Kanagal-Shamanna, Alex Bataller, Guillermo Montalban-Bravo, Irene Ganan-Gomez, Yue Wei, Hui Yang, Kelly S. Chien, Danielle Hammond, Carlos E. Bueso-Ramos, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 6952–6954.

https://doi.org/10.1182/blood-2022-165488

Published: 2022

Journal Articles

Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial

Guillermo Garcia-Manero, Vera Adema, Samuel Urrutia, Feiyang Ma, Hui Yang, Irene Ganan-Gomez, Gautam Borthakur, Koichi Takahashi, Nicholas Short, Ghayas C. Issa, Kelly S. Chien, Guillermo Montalban-Bravo, Joby Joseph, Simona Colla

Blood (2022) 140 (Supplement 1): 2078–2080.

https://doi.org/10.1182/blood-2022-167703

Published: 2022

Journal Articles

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Blood (2022) 140 (Supplement 1): 2232–2233.

https://doi.org/10.1182/blood-2022-160294

Published: 2022

NARROW

Characteristics and Survival Outcome of Patients with Isolated 11q Deletion Myelodysplastic Syndromes

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4 + T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Application of Next-Generation Cytogenetics in a Clinical Laboratory for Diagnostic Work-up of Myelodysplastic Syndromes/Neoplasms (MDS)

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Prolymphocytic Leukemia: Two Case Reports

CDC2-like Kinases (CLKs) Inhibition As a Novel Targeted Therapeutic Strategy in Myelodysplastic Syndromes (MDS)

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones

Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

A Phase 2 Study of Canakinumab in Patients with Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Sting-Mediated Interferon Signaling Exerts Potent Antileukemic Effects in High-Risk Myeloid and Monocytic Malignancies

Demographic Characteristics and Treatment Patterns in Veterans with Multiple Myeloma: A Comprehensive Analysis from the Veterans Affairs Database (2000-2020)

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN)

No Benefits from Glucocorticoid Maintenance Therapy in Patients with PNH

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only